The Clinical Protocol and Data Management Core (CPDMC) is a collaborative integrated unit staffed by professionals with expertise in protocol data management and clinical research informatics, to provide centralized infrastructure and support for the effective efficient conduct of clinical research. Working closely with the Biostatistics Core, this team blends technical and scientific expertise to provide City of Hope investigators with world-class research support and informatics solutions for clinical trials, observational studies, and outcomes research. The CPDMC offers comprehensive services to COH Cancer Center members including: protocol document management, electronic data capture, standardized clinical research staff training and education, honest broker process for accessing tissue samples, study recruitment tracking, patient safety decision support tools, data quality assurance and monitoring, multisite coordination, and customized and routine reports, including CCSG Summaries 3 and 4. The CPDMC provides input into developing protocols with respect to practicality and appropriateness of protocol management, study calendar, and data collection issues. Data Quality Monitors ensure that study research staff are fully trained in protocol management, data collection, and overall study conduct according to Good Clinical Practice (GCP) and COH policies. The CPDMC database monitors ensure that protocol and patient registration is carried out according to NCI guidelines. Key informatics services provided include;Clinical Trial Management Systems to manage planning, execution, and reporting of clinical research studies;Electronic Data Capture to provide electronic case report forms;and Clinical Research Decision Support to translate data into scientific decisions. Our emerging work on Translational Research Informatics includes implementation of the enterprise data warehouse, i2b2 open source system for cohort selection for tissue correlative studies, along with Electronic Lab Notebook and Laboratory Information Management Systems. For all these functions we use international architectural and vocabulary standards and project management methodologies to deliver clinical and translational informatics applications. In summary, the CPDMC delivers resources, education, and information management processes to establish best practices in accordance with FDA, GCP, regulatory requirements such as 21 CFR Part 11, and international data standards such as HL7, SNOMED, and LOINC The Core's services are available to all COH faculty, with COH Cancer Center members receiving the highest priority.
The overall goal of the Clinical Protocol and Data Management core facility is to provide centralized infrastructure and support for effective, efficient conduct of clinical research including protocol document management, electronic data capture, standardized training and education, study tracking, patient safety decision support tools, quality assurance and monitoring and reporting. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.
|Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33|
|Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68|
|Salhotra, A; Tsai, N; Thomas, S H et al. (2015) Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 50:139-41|
|Ali, H; Palmer, J; Eroglu, Z et al. (2015) Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. Bone Marrow Transplant 50:307-9|
|Behrendt, Carolyn E; Hurria, Arti; Tumyan, Lusine et al. (2014) Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer. J Natl Compr Canc Netw 12:1579-85|
|Yang, Lixin; Perez, Aldwin Apollo; Fujie, Sayuri et al. (2014) Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 14:124|
|Gillis, Peter A; Hernandez-Alvarado, Nelmary; Gnanandarajah, Josephine S et al. (2014) Development of a novel, guinea pig-specific IFN-? ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine. Vaccine 32:3963-70|
|Chen, Shiuan; Zhou, Dujin; Hsin, Li-Yu et al. (2014) AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci 139:198-209|
|Bhatia, Smita; Landier, Wendy; Hageman, Lindsey et al. (2014) 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 124:2345-53|
|Sun, Virginia; Grant, Marcia; McMullen, Carmit K et al. (2014) From diagnosis through survivorship: health-care experiences of colorectal cancer survivors with ostomies. Support Care Cancer 22:1563-70|
Showing the most recent 10 out of 912 publications